Thus, modern pharmacology must consider the possibility of evaluating the OCT1 profile regarding expression/function in the healthy liver and in the target tissue, particularly if this is a tumor, of each patient in order to predict the lack of response and to design an individualized pharmacological regimen with the highest likelihood of success. This evidence concerns the gene SLC22A1 and neoplasm.